Rua Bioscience (RUA) investor relations material

Opening remarks and agenda

• The AGM on 20 October 2026 covered the Chair’s address, FY26 results and operating updates, shareholder questions, six ordinary resolutions and general business.

• Shareholders and proxies could submit questions and vote online; unanswered questions would receive an email response.

Financial performance review

• FY26 revenue and other income reached NZD 2.9m; customer revenue rose 71% to NZD 2.58m from NZD 1.51m.

• Loss before tax was NZD 3.36m, a 3% improvement YoY; excluding financing costs and one-off inventory impairments, loss narrowed 7% to NZD 3.07m.

• At 30 June 2026, assets were NZD 7.17m, liabilities NZD 2.92m, net assets NZD 4.25m and cash and investments NZD 534,000.

• Operating activities used NZD 2.96m net cash, compared with NZD 2.79m in FY25; financing activities provided NZD 3.24m.

• New Zealand revenue rose to NZD 1.3m from NZD 440,000 and Australia to NZD 1.03m from NZD 585,000; Europe revenue fell to NZD 261,000 from NZD 487,000.

Board and executive committee updates

• Anna Stove was Chair; Panapa Ehau was Executive Director and co-founder; Teresa Ciprian and Tony Barclay were non-executive directors, with Barclay chairing the Audit, Finance and Risk Committee.

• Keith Zhou was nominated for election; his experience spans international trade, logistics, consumer health manufacturing and Asian markets.

• Paul Naske presented operating and market updates, while CFO Liam Walker reviewed FY26 financial results.